How does Parkinson’s prevalence differ in high-income versus low-income countries, what percentage are affected, and how do treatment access levels compare?

The Parkinson’s Protocol™ By Jodi Knapp Thus, the eBook, The Parkinson’s Protocol, educates you regarding the natural and simple ways to minimize the symptoms and delay the development of Parkinson’s effectively and quickly. It will also help your body to repair itself without following a specific diet plan, using costly ingredients or specific equipment. Its 60 days guarantee to return your money allows you to try for once without any risk.

How does Parkinson’s prevalence differ in high-income versus low-income countries, what percentage are affected, and how do treatment access levels compare?

🌍 A Tale of Two Worlds: Parkinson’s Prevalence in High- vs. Low-Income Countries

The prevalence of Parkinson’s disease, a progressive neurodegenerative disorder, displays a significant and paradoxical difference between high-income and low-income countries. On the surface, the data consistently shows that high-income countries in North America, Europe, and Australia have a much higher reported prevalence and incidence of Parkinson’s disease compared to low- and middle-income countries (LMICs) in regions like sub-Saharan Africa and Southeast Asia. However, this is not a simple story of a “disease of affluence.” This disparity is largely believed to be a reflection of two key factors: differences in population age structure and vastly different levels of healthcare access and diagnostic capabilities. Age is the single greatest risk factor for Parkinson’s disease, and high-income countries have significantly older populations, with a much larger proportion of citizens living into their 70s, 80s, and beyond. This “survivor effect” means there is a larger pool of people living to the age where Parkinson’s is most likely to develop. In contrast, many low-income countries have much younger population pyramids. However, a growing body of evidence suggests that the true prevalence in LMICs is severely underestimated due to a lack of diagnostic resources, limited public awareness, and a shortage of healthcare professionals trained to recognize the disease. As populations in LMICs begin to age and diagnostic capabilities improve, the global burden of Parkinson’s is expected to shift dramatically, with the largest increase in cases projected to occur in these developing regions.

📊 The Numbers Game: Percentage of Populations Affected

When examining the percentage of the population affected by Parkinson’s disease, the difference between high-income and low-income nations is stark.

High-Income Countries: In nations with well-established healthcare systems and older populations, the prevalence rates are well-documented. In Europe and North America, the prevalence of Parkinson’s disease is typically reported to be in the range of 100 to 300 cases per 100,000 people in the general population. However, this number is highly age-dependent. In the population aged 65 and over, the prevalence rises dramatically to approximately 1% to 2%. This means that for every 100 people over the age of 65, one or two are living with Parkinson’s.
Low-Income Countries: The reported prevalence in many low-income countries, particularly in sub-Saharan Africa, is often significantly lower, with some studies reporting rates as low as 20 to 60 cases per 100,000 people. This lower figure is a reflection of the challenges in diagnosis and the younger average age of the population. However, when age-adjusted studies are conducted, the gap begins to narrow, suggesting that the underlying risk is not as different as the crude numbers might suggest. The “Parkinson’s pandemic” is a term used by neurologists to describe the projected explosion in cases in regions like Asia and South America as their populations age

💊 A Chasm of Care: Comparing Treatment Access Levels

The comparison of treatment access for Parkinson’s disease between high-income and low-income countries reveals a profound and life-altering disparity. It is a chasm that separates a manageable chronic illness in one part of the world from a rapidly disabling and devastating condition in another.

High-Income Countries: In wealthy nations, patients typically have access to a comprehensive system of care. This includes access to specialist neurologists who have expertise in diagnosing and managing movement disorders. Critically, there is near-universal access to the gold-standard medication for Parkinson’s, levodopa, as well as a wide array of other drug classes to manage motor symptoms and non-motor complications. Patients also often have access to multidisciplinary care, including physical therapy, occupational therapy, and speech therapy, all of which are essential for maintaining function. For advanced cases, sophisticated treatments like deep brain stimulation (DBS) are available. While challenges still exist, the standard of care is to provide continuous and optimized treatment to manage symptoms and maximize quality of life for as long as possible.
Low-Income Countries: The situation in many low-income countries is dire. There is a severe shortage of neurologists; in some African countries, there may be only a handful of neurologists for a population of millions. This means that diagnosis is often severely delayed or missed altogether. The most critical issue is the lack of access to essential medications. Levodopa, which is on the World Health Organization’s list of essential medicines, is often unavailable, unaffordable, or in inconsistent supply. A survey in sub-Saharan Africa found that the availability of levodopa in public health facilities was close to zero. Without this fundamental medication, patients are left to suffer the full, unmitigated progression of the disease’s debilitating motor symptoms. Access to supportive therapies like physical therapy is virtually non-existent for the vast majority of the population, and advanced therapies like DBS are completely out of reach. This lack of access transforms Parkinson’s from a treatable condition into a rapid sentence of severe disability and social isolation.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more